CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies

• Published in: Atherosclerosis Vol. 278; pp. 49 - 59
• Main Authors: Reiss, Allison B., Miyawaki, Nobuyuki, Moon, Jane, Kasselman, Lora J., Voloshyna, Iryna, D'Avino, Robert, De Leon, Joshua
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.11.2018
• Subjects: Atherosclerosis; CKD-MBD; Phosphate; Vascular calcification; Vitamin D; Vascular calcification; Vitamin D; Phosphate; CKD-MBD; Atherosclerosis
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2018.08.046

Mineral bone disease (MBD) is a common complication of chronic kidney disease (CKD) characterized by disruption of normal mineral homeostasis within the body. One or more of the following may occur: hypocalcemia, hyperphosphatemia, secondary hyperparathyroidism (SHPT), decreased vitamin D and vascular calcification (VC). The greater the decrease in renal function, the worse the progression of CKD-MBD. These abnormalities may lead to bone loss, osteoporosis and fractures. CKD-MBD is a major contributor to the high morbidity and mortality among patients with CKD. Another well-known complication of CKD is cardiovascular disease (CVD) caused by increased atherosclerosis and VC. CVD is the leading cause of morbidity and mortality in CKD patients. VC is linked to reduced arterial compliance that may lead to widened pulse pressure and impaired cardiovascular function. VC is a strong predicator of cardiovascular mortality among patients with CKD. Elevated phosphorus levels and increased calcium-phosphorus product promote VC. Controlling mineral disturbances such as hyperphosphatemia and SHPT is still considered among the current strategies for treatment of VC in CKD through restriction of calcium based phosphate binders in hyperphosphatemic patients across all severities of CKD along with dietary phosphate restriction and use of calciminetics. Additionally, Vitamin D insufficiency is common in CKD and dialysis patients. The causes are multifactorial and a serious consequence is SHPT. Vitamin D compounds remain the first-line therapy for prevention and treatment of SHPT in CKD. Vitamin D may also have atheroprotective effects on the arterial wall, but clinical studies do not show clear evidence of reduced cardiovascular mortality with vitamin D administration. This review discusses the issues surrounding CKD-MBD, cardiovascular disease and approaches to treatment. •Mineral bone disease is a common complication of chronic kidney disease (CKD).•Hypocalcemia, hyperphosphatemia, secondary hyperparathyroidism (SHPT) occur.•Complication of CKD is atherosclerosis and vascular calcification.•Vascular calcification is predicator of cardiovascular mortality among CKD patients.•Current treatment strategies consist of controlling mineral disturbances.